Single User License
INR 238070
Site License
INR 476140
Corporate User License
INR 714210

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Pipeline Review, H2 2016

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Pipeline Review, H2 2016', provides in depth analysis on GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted pipeline therapeutics.

The report provides comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects

The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Overview 7

Therapeutics Development 8

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Products under Development by Stage of Development 8

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Products under Development by Therapy Area 9

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Products under Development by Indication 10

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Pipeline Products Glance 11

Early Stage Products 11

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Products under Development by Companies 12

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Products under Development by Universities/Institutes 14

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Companies Involved in Therapeutics Development 21

Aurigene Discovery Technologies Limited 21

Boehringer Ingelheim GmbH 22

Horizon Discovery Group Plc 23

Nimbus Therapeutics, LLC 24

Nuevolution AB 25

PeptiDream Inc. 26

Tosk, Inc. 27

Warp Drive Bio, Inc. 28

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Drug Profiles 29

ARS-853-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AZD-4785-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HD-001-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

MM-41-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecule to Inhibit KRAS for Oncology-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules 1 to Inhibit K-Ras for Oncology-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules 2 to Inhibit K-Ras for Oncology-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules 3 to Inhibit Ki-Ras for Oncology-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Inhibit K-Ras for Oncology-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Inhibit K-Ras for Oncology-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules to Inhibit KRAS for Oncology-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Inhibit KRas for Solid Tumor-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecules to Inhibit KRAS2B for Oncology-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SML-8731-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Vaccine to Target K-RAS for Lung Cancer-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Dormant Projects 46

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)-Featured News & Press Releases 47

Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation 47

May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21

Pipeline by Boehringer Ingelheim GmbH, H2 2016 22

Pipeline by Horizon Discovery Group Plc, H2 2016 23

Pipeline by Nimbus Therapeutics, LLC, H2 2016 24

Pipeline by Nuevolution AB, H2 2016 25

Pipeline by PeptiDream Inc., H2 2016 26

Pipeline by Tosk, Inc., H2 2016 27

Pipeline by Warp Drive Bio, Inc., H2 2016 28

Dormant Projects, H2 2016 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aurigene Discovery Technologies Limited

Boehringer Ingelheim GmbH

Horizon Discovery Group Plc

Nimbus Therapeutics, LLC

Nuevolution AB

PeptiDream Inc.

Tosk, Inc.

Warp Drive Bio, Inc.

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Therapeutic Products under Development, Key Players in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Therapeutics, GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Pipeline Overview, GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Pipeline, GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com